(RTTNews) - Pfizer Inc. (PFE) on Tuesday announced positive topline results from the Phase 2b VESPER-3 study evaluating monthly maintenance dosing of its ultra-long-acting, injectable GLP-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results